🌍📈🧬 #Epidemiology of #RenalCancer: #Incidence, #Mortality, #Survival, #GeneticPredisposition, and #RiskFactors https://t.co/YKFXuvZzP9 Up-to -date facts and figures together with future projections at @EUplatinum

👩‍⚕️👨‍⚕️ #SIULIVE torna in presenza! 🏥 Un evento unico in ambito urologico che presenta, in diretta, interventi di chirurgia urologica eseguiti “a casa propria” da colleghi italiani e stranieri. #Urologia

Proud to share our experience from the @SanRaffaeleMI #VHL Program assessing PROMs in VHL 🔑VHL patients show more depression than those with sporadic RCC 🧠Psychological support must be part of SoC for hereditary cancer syndromes! @VHLAlliance @JCOOA_ASCO https://t.co/NWkxD3m8jk

Lymphovascular Invasion in #kidneycancer increases risk of mortality in stage T1-T3a; impact = to upstaging by 1 stage. Data call for consideration of T1b/T2 for adjuvant therapy #clinicaltrials @kcCURE @KidneyCancer @EAU_Uroonco @MichaelStaehler https://t.co/Ug9fbsGNoE

🚨 New paper! 🔬 Biopsy-all strategy for renal masses vs ⚡ Immediate surgery Simulation results (1,729 pts): 6.7% surgeries avoided ↓ complications (−3%, −2.5% severe) 💰 $840 saved/patient 👉 https://t.co/66JXbom7nO Should biopsy be the new standard? @_alelarcher

Congratulations to @crisbergerot on the publication of this paper in @EurUrolOncol and for all the great work she is doing in the field! @MRoupret @Ric_Campi @RenuEapen

Claim your spot for #RENALC25, an interactive meeting translating the latest evidence on renal cell cancer into clinical practice! ➡️Register here: https://t.co/MR8D6Tiwrh and join us on December 3rd, in Lisbon or online! 🇵🇹💻 @PignotG @Ric_Campi @OncoAlert

It's impossible to get bored this summer🏖️! So much to read and so many news that give energy and enthusiasm to the hard work of clinical oncologists like me, who cure hundreads of patients with @KidneyCancer and #UC! ⬆️ Rising the bar!! #QoL #OS #Care #Thankful #CancerResearch

📢 MRI-led active surveillance for #ProstateCancer in 1150 men: 🧠 2 in 3 avoided biopsy at 5y 📉 91% EFS in MRI-invisible Gleason 3+3 ⚠️ Only 5% progressed to ≥Gleason 4+3 📚 Published in European Urology 🔗 https://t.co/oGkk4iWwiR #UroTwitter #MRI #Urology #PCa

📢 JAMA Oncol phase 2 trial: sintilimab + axitinib in advanced FH-deficient RCC (n=41) @JAMAOnc ✅ ORR 56% (4 CR, 19 PR) ✅ Median PFS 19.8 mo ✅ 12-mo OS 95% ⚠️ Safety: 95% any TRAE, 32% grade ≥3 Most common: proteinuria 63%, hyperTG 59% https://t.co/w9apehTWLF #kidneycancer

🌎 Renal cancer burden is rising: 434,840 new cases and 155,953 deaths in 2022, projected to reach 745,791 cases (+72%) and 304,861 deaths (+96%) by 2050. Genetics and modifiable risks like obesity, HTN, and smoking are key drivers. 📖 @EUplatinum DOI 👉🏻

📢 New in Prostate Cancer Guidelines – But Mind the Differences! The 2025 EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines bring a major update: 🔹 A new classification for intermediate-risk localized prostate cancer, moving away from the D’Amico system. 🔹 Subdivision into favourable

Lesson learned from the comparison of #Robotic vs #Open #partialnephrectomy in the OpeRa trial published today in @Annals_Oncology https://t.co/gQYBYHr7fJ 1️⃣ PN has #complications. Studies reporting 0% complications are likely conducted by bad researchers rather than by good

🌍📈🧬 #Epidemiology of #RenalCancer: #Incidence, #Mortality, #Survival, #GeneticPredisposition, and #RiskFactors https://t.co/YKFXuvZzP9 Up-to -date facts and figures together with future projections at @EUplatinum

@EUplatinum @Ric_Campi @FreddieBray_ @EJonasch @AhJemal @LauraMarandino @vmollica7 @KidneyCancerDoc @MaxineGBTran @uretericbud @Uroweb @Albert0Briganti @IARCWHO @GICR_IARC @GLOBOCAN_GCO @VHLAlliance @IKCCorg @AmerUrological @CanUrolAssoc @myESMO @GeneticCouns @NCCN 9. This paper has become a classic in @EUplatinum. We took-off from the previous epidemiological studies: https://t.co/64JRK1nseP by @u_capitanio https://t.co/Ov7Zx7wCXe by @LauraBukavinaMD 🙏Truly inspirational!🙏

How do outcomes compare when salvage robotic radical prostatectomy (sRARP) follows focal therapy vs. radiation therapy? 📌 Key Findings: •Patients post-RT had more aggressive tumors and worse metastasis-free and overall survival, but only before adjustment. •sRARP after FT is

Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors! @EUplatinum @_alelarcher @Ric_Campi @LauraBukavinaMD @LauraMarandino @KidneyCancerDoc @uretericbud @Uroweb https://t.co/Jl9l6dg0B4

@EUplatinum @Ric_Campi @FreddieBray_ @EJonasch @AhJemal @LauraMarandino @vmollica7 @KidneyCancerDoc @MaxineGBTran @uretericbud @Uroweb @Albert0Briganti @IARCWHO @GICR_IARC @GLOBOCAN_GCO @VHLAlliance @IKCCorg 8. Many international #guidelines provide indications for genetic testing in #RCC 🧬🧬🧬 @AmerUrological @CanUrolAssoc @Uroweb @myESMO @GeneticCouns @NCCN 1️⃣ Age 2️⃣ Multifocal/bilateral tumor 3️⃣ Family history of RC 4️⃣ Specific histological features 5️⃣Extrarenal features

@EUplatinum @Ric_Campi @FreddieBray_ @EJonasch @AhJemal @LauraMarandino @vmollica7 @KidneyCancerDoc @MaxineGBTran @uretericbud @Uroweb @Albert0Briganti @IARCWHO @GICR_IARC @GLOBOCAN_GCO @VHLAlliance @IKCCorg 7. 📊 #Incidence and #mortality inform policymaking 📉 #Survival informs clinical management Both are essential for patients #RenalCancer is currently not contemplated among the primary tumours indexed in #SURVMARK-2 and #SURVCAN. Possible inclusion soon? @IARCWHO @GICR_IARC

@EUplatinum @Ric_Campi @FreddieBray_ @EJonasch @AhJemal @LauraMarandino @vmollica7 @KidneyCancerDoc @MaxineGBTran @uretericbud @Uroweb @Albert0Briganti @IARCWHO @GICR_IARC @GLOBOCAN_GCO @VHLAlliance @IKCCorg 6. The lack of #diversity in #genomic databases and overrepresentation of individuals of European ancestry represents a significant issue that limits the generalizability of findings on a global scale 🌐 See also:

@EUplatinum @Ric_Campi @FreddieBray_ @EJonasch @AhJemal @LauraMarandino @vmollica7 @KidneyCancerDoc @MaxineGBTran @uretericbud @Uroweb @Albert0Briganti @IARCWHO @GICR_IARC @GLOBOCAN_GCO @VHLAlliance @IKCCorg 5. #RenalCancer cases and deaths stratified according to #HumanDevelopmentIndex 🚀 may serve as indirect indicators of #disparities in #healthcare access, variability in #screening programs, differences in data collection methods, and inconsistencies in #disease classification